RAMM PHARMA CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.04 CAD | 0.00% |
|
0.00% | -27.27% |
| 29/03 | RAMM Pharma Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024 | CI |
| 19/03 | RAMM Pharma Corp. cancelled the transaction announced on September 5, 2023 | CI |
Valuation
| Fiscal Period: October | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 54.85 | 57.4 | 24.48 | 5.969 |
| Enterprise Value (EV) 1 | 26.94 | 40.28 | 15.39 | 1.258 |
| P/E ratio | -7.44 x | -7.1 x | -1.17 x | -0.78 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 10.1 x | 13.9 x | 6.28 x | 1.18 x |
| EV / Revenue | 4.95 x | 9.79 x | 3.95 x | 0.25 x |
| EV / EBITDA | -3.72 x | -6.71 x | -2.2 x | -0.21 x |
| EV / FCF | -1,43,35,704 x | -80,13,662 x | -40,55,738 x | -5,44,112 x |
| FCF Yield | -0% | -0% | -0% | -0% |
| Price to Book | 1.53 x | 1.02 x | 0.69 x | 0.2 x |
| Nbr of stocks (in thousands) | 99,723 | 1,23,449 | 1,22,400 | 1,19,389 |
| Reference price 2 | 0.5500 | 0.4650 | 0.2000 | 0.0500 |
| Announcement Date | 01/03/21 | 22/03/22 | 28/02/23 | 29/02/24 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: October | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 8.346 | 5.611 | 5.445 | 4.116 | 3.897 | 5.065 |
| EBITDA 1 | 0.3959 | -1.857 | -7.235 | -6.007 | -7.003 | -6.037 |
| EBIT 1 | 0.3856 | -1.875 | -7.576 | -6.642 | -7.937 | -7.086 |
| Operating Margin | 4.62% | -33.41% | -139.14% | -161.37% | -203.64% | -139.9% |
| Earnings before Tax (EBT) 1 | -0.6789 | -6.815 | -7.426 | -7.101 | -20.95 | -7.711 |
| Net income 1 | -0.6846 | -6.82 | -7.431 | -7.107 | -20.96 | -7.721 |
| Net margin | -8.2% | -121.56% | -136.47% | -172.66% | -537.79% | -152.43% |
| EPS 2 | -0.0137 | -0.1353 | -0.0739 | -0.0655 | -0.1707 | -0.0638 |
| Free Cash Flow | - | 2.558 | -1.879 | -5.026 | -3.795 | -2.312 |
| FCF margin | - | 45.6% | -34.52% | -122.12% | -97.36% | -45.64% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 28/02/20 | 28/02/20 | 01/03/21 | 22/03/22 | 28/02/23 | 29/02/24 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: October | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 4.31 | - | - | - | - | - |
| Net Cash position 1 | - | 33.1 | 27.9 | 17.1 | 9.09 | 4.71 |
| Leverage (Debt/EBITDA) | 10.88 x | - | - | - | - | - |
| Free Cash Flow | - | 2.56 | -1.88 | -5.03 | -3.79 | -2.31 |
| ROE (net income / shareholders' equity) | - | -36% | -20.1% | -15.4% | -45.6% | -23.7% |
| ROA (Net income/ Total Assets) | - | -4.72% | -11.9% | -8.57% | -10% | -12.4% |
| Assets 1 | - | 144.4 | 62.66 | 82.93 | 209.4 | 62.36 |
| Book Value Per Share 2 | -0 | 0.3800 | 0.3600 | 0.4600 | 0.2900 | 0.2500 |
| Cash Flow per Share 2 | 0.0200 | 0.3500 | 0.2800 | 0.1400 | 0.0800 | 0.0400 |
| Capex 1 | 0.02 | 0.39 | 0.28 | 0.43 | 0.17 | 0.06 |
| Capex / Sales | 0.25% | 6.91% | 5.09% | 10.46% | 4.31% | 1.23% |
| Announcement Date | 28/02/20 | 28/02/20 | 01/03/21 | 22/03/22 | 28/02/23 | 29/02/24 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -27.27% | 3.51M | |
| +33.63% | 50.93B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B |
- Stock Market
- Equities
- RAMM Stock
- Financials RAMM Pharma Corp.
